BR9809629A - Agente terapêutico para caquexia - Google Patents

Agente terapêutico para caquexia

Info

Publication number
BR9809629A
BR9809629A BR9809629-0A BR9809629A BR9809629A BR 9809629 A BR9809629 A BR 9809629A BR 9809629 A BR9809629 A BR 9809629A BR 9809629 A BR9809629 A BR 9809629A
Authority
BR
Brazil
Prior art keywords
cachexia
parathyroid hormone
related peptide
therapeutic agent
inhibiting
Prior art date
Application number
BR9809629-0A
Other languages
English (en)
Inventor
Koh Sato
Toshiaki Tsunenari
Kimie Ishii
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR9809629A publication Critical patent/BR9809629A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Massaging Devices (AREA)
  • Valve Device For Special Equipments (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<B>"AGENTE TERAPêUTICO PARA CAQUEXIA"<D>. A invenção refere-se a um agente terapêutico para caquexia compreendendo, como um ingrediente ativo, uma substância capaz de inibir a ligação entre proteína relacionada a hormónio paratiróide (PTHrP) e um seu receptor.
BR9809629-0A 1997-05-15 1998-05-13 Agente terapêutico para caquexia BR9809629A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12550597 1997-05-15
JP19444597 1997-07-18
PCT/JP1998/002116 WO1998051329A1 (fr) 1997-05-15 1998-05-13 Remede contre la cachexie

Publications (1)

Publication Number Publication Date
BR9809629A true BR9809629A (pt) 2000-07-04

Family

ID=26461935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809629-0A BR9809629A (pt) 1997-05-15 1998-05-13 Agente terapêutico para caquexia

Country Status (19)

Country Link
US (2) US20020165363A1 (pt)
EP (1) EP1004313B1 (pt)
KR (1) KR100508338B1 (pt)
CN (1) CN1329080C (pt)
AT (1) ATE361099T1 (pt)
AU (1) AU750021C (pt)
BR (1) BR9809629A (pt)
CA (1) CA2289910A1 (pt)
DE (1) DE69837707T2 (pt)
ES (1) ES2285769T3 (pt)
HK (1) HK1029047A1 (pt)
IL (1) IL132896A0 (pt)
NO (1) NO995558L (pt)
PL (1) PL193575B1 (pt)
SK (1) SK155799A3 (pt)
TR (1) TR199902800T2 (pt)
TW (1) TWI227140B (pt)
UA (1) UA74130C2 (pt)
WO (1) WO1998051329A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
WO2001002011A1 (fr) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
EP1312378A4 (en) * 2000-08-16 2004-03-17 Chugai Pharmaceutical Co Ltd AGENTS FOR THE RELIEF OF SYMPTOMS CAUSED BY JOINT DISEASES
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2008144763A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2009120836A1 (en) * 2008-03-26 2009-10-01 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9724410B2 (en) 2009-11-24 2017-08-08 Alderbio Holdings Llc Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
CA2825165C (en) 2011-01-31 2018-07-03 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
KR20210025132A (ko) 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US9730984B2 (en) 2012-05-11 2017-08-15 Gemvax & Kael Co., Ltd. Composition for preventing or treating rheumatoid arthritis
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN104508485B (zh) 2013-06-07 2017-01-18 杰姆维克斯&凯尔有限公司 在癌症免疫疗法中有用的生物标记
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
RU2661596C2 (ru) 2013-10-23 2018-07-17 Джемвакс Энд Каэл Ко., Лтд. Композиция для лечения и профилактики доброкачественной гиперплазии простаты
ES2818921T3 (es) 2013-11-22 2021-04-14 Gemvax & Kael Co Ltd Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20230028596A (ko) 2016-04-07 2023-02-28 김상재 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
EP0293130A3 (en) 1987-05-26 1990-06-13 Merck & Co. Inc. Dimers of parathyroid hormone antagonists
US5001223A (en) 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5217896A (en) * 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
JPH02207099A (ja) 1989-02-07 1990-08-16 Tonen Corp ＰＴＨｒＰ関連ペプチド、その製造法及び用途
CA2035179C (en) 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
EP0539491A1 (en) * 1990-07-13 1993-05-05 The Regents Of The University Of California PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9
CA2107569C (en) 1991-04-05 2011-08-02 Gino V. Segre Parathyroid hormone receptor and dna encoding same
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
WO1993013133A1 (en) 1991-12-20 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3504697B2 (ja) 1993-09-30 2004-03-08 株式会社先端生命科学研究所 ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
JPH07316195A (ja) 1994-05-25 1995-12-05 Nippon Kayaku Co Ltd 新規なＰＴＨｒＰ関連ペプチド及びその用途
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5626845A (en) * 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
EP0813423B1 (en) * 1995-01-23 2002-07-03 Xenotech Incorporated Composition to inhibit osteolysis and metastasis
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
DE69637104T2 (de) 1995-02-20 2008-01-31 Yukio Kato Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
ES2153564T3 (es) 1995-03-01 2001-03-01 Stryker Corp Regeneracion de la dentina inducida por un morfogeno.
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
US5660826A (en) 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
EP1166796A3 (en) 1996-02-01 2002-03-06 Chugai Seiyaku Kabushiki Kaisha Agents for preventing and treating thrombocytopenia
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
JP4372240B2 (ja) 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
JP4414494B2 (ja) 1998-02-03 2010-02-10 旭化成ファーマ株式会社 白血球減少症の予防剤および治療剤
ES2302374T3 (es) 1998-05-05 2008-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compuesto selectivo de receptores pth2.
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
CA2332128A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis

Also Published As

Publication number Publication date
PL193575B1 (pl) 2007-02-28
CN1329080C (zh) 2007-08-01
PL336797A1 (en) 2000-07-17
DE69837707T2 (de) 2008-01-10
TR199902800T2 (xx) 2000-04-21
CA2289910A1 (en) 1998-11-19
AU750021C (en) 2003-10-16
EP1004313B1 (en) 2007-05-02
NO995558D0 (no) 1999-11-12
IL132896A0 (en) 2001-03-19
AU7236998A (en) 1998-12-08
DE69837707D1 (de) 2007-06-14
KR100508338B1 (ko) 2005-08-17
NO995558L (no) 2000-01-12
EP1004313A1 (en) 2000-05-31
TWI227140B (en) 2005-02-01
AU750021B2 (en) 2002-07-11
UA74130C2 (uk) 2005-11-15
EP1004313A4 (en) 2005-01-19
SK155799A3 (en) 2000-06-12
CN1255858A (zh) 2000-06-07
ATE361099T1 (de) 2007-05-15
US7468184B2 (en) 2008-12-23
ES2285769T3 (es) 2007-11-16
HK1029047A1 (en) 2001-03-23
KR20010012613A (ko) 2001-02-15
US20030138424A1 (en) 2003-07-24
US20020165363A1 (en) 2002-11-07
WO1998051329A1 (fr) 1998-11-19

Similar Documents

Publication Publication Date Title
BR9809629A (pt) Agente terapêutico para caquexia
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
IL152384A0 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
HK1059040A1 (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
LV12354A (lv) Centralo kanabinoidreceptoru antagonistu pielietojums estgribas regulesanai
DE69839270D1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
ITRM940805A0 (it) Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
AU6420798A (en) A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
CY1108180T1 (el) Προληπτικα ή/και θεραπευτικα για συστημικο ερυθηματωδη λυκο που περιεχουν αντισωμα αντι-il-6 υποδοχεα ως το δραστικο συστατικο
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
DE60229435D1 (de) Kondensierte heterocyclische succinimidverbindungen und deren analoga, modulatoren der funktion von nukleären hormonrezeptoren
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
NO20004215L (no) Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav
HUP0102380A2 (hu) Terápiás készítmény hiperkalcémiás krízis kezelésére
EP1354896A4 (en) NEW MONOCLONAL ANTIBODY
DK1044064T3 (da) Overtrækningsindretning til granula til indtagelse ad oral vej
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
DK266289D0 (da) Alfa-adrenerge receptorantagonister, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse antagonister
ITTO930537A0 (it) Dispositivo programmabile di controllo di infusori portatili di farma-ci, particolarmente per terapie ferrochelanti e simili.
ZA200208518B (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein.
BR0012467A (pt) Agente terapêutico para hipercalcemia resistente à droga
TH18051B (th) สารผสมฆ่าแมลง

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.